AMSBIO introduces highly efficient substrate for culturing ES/iPS cells
iMatrix recombinant Laminin-511 E8 protein fragments permit ES/iPS cells to be maintained in xeno-free, feeder-free culture conditions enabling easy application in medical trials.
iMatrix recombinant Laminin-511 E8 fragments from AMSBIO is an innovative cell culture matrix compatible with a wide variety of cell types, and exceptionally well suited for pluripotent stem cells.
Laminin-511 is a major component of the basement membrane, which is expressed in early development of the embryo and can be used as a matrix for pluripotent (ES/iPS) stem cells, as it binds to integrin on cell surfaces. However, Laminin-511 is a large protein (800kDa) composed of three chains (alpha, beta and gamma) forming a supramolecular aggregate, making it difficult to produce recombinantly. In order to overcome this challenge, Laminin-511 proteins were fragmented to find the smallest integrin-binding component and hES cells were found to adhere more strongly to the E8 fragment than to the full-length protein.
iMatrix recombinant Laminin-511 E8 protein fragments from AMSBIO permit ES/iPS cells to be maintained in xeno-free, feeder-free culture conditions enabling easy application in medical trials. In an independent study iMatrix and other cell culture substrates were compared for their strength in adhering to hES cells. The study showed that the iMatrix adhered to cells more strongly than to Matrigel or full-length Laminin and Vitronectin cell culture matrices.
AMSBIO iMatrix recombinant Laminin-511 E8 protein fragments also demonstrates highly efficient bulk cell proliferation. Using iMatrix it is possible to achieve a 1,000-fold increase in numbers of ES/iPS cells after one month culture, this is 200 times more than using the conventional colony method.
In addition, using the iMatrix recombinant Laminin-511 E8 fragment as a cell culture matrix enables you to culture single ES/iPS cells almost immediately, thereby reducing the time required to optimize culture methods and drastically enhancing efficiency of cell cultures.
AMSBIO's recombinant iMatrix Laminin-511 E8 protein fragments can be used pre-mixed as well as in conventional pre-coating techniques. Pre-mixing saves time and money for as less material is required and there is no need to pre-coat dishes.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.